

Office of Strategy Management

BALANCED SCORECARD SUMMARY REPORT

January – December 2019



STRATEGY MAP 2019-2022

VISION The Philippine Heart Center is the leader in upholding the highest standards of cardiovascular care, a self-reliant institution responsive to the health needs of the Filipino people by 2022

Better health outcomes in Cardiovascular diseases and Responsive Health System

Healthier Filipino Hearts

Position Philippine Heart Center as the leader in cardiovascular care at par with global benchmarks

Position Philippine Heart Center as the country's lead advocate in the prevention of cardiovascular diseases

Provide comprehensive and responsible patient care using multi-disciplinary best practice standards

Expand local and international training for advanced cardiovascular procedures

Prioritize institutional research on advanced cardiovascular procedures to impact national health policies

Strengthen linkages with stakeholders for prevention and treatment of CV diseases nationwide

Provide comprehensive
Employee Career training and
progression pathway to
enhance employee
engagement

Promote heartfelt cardiovascular care through positive patient experience

Upgrade hospital facilities for positive practice environment and stakeholders' satisfaction

Provide technology solutions to improve operational efficiency

Ensure prudent and efficient asset management

MISSION We shall provide comprehensive cardiovascular care enhanced by education and research that is accessible to all

CORE VALUES Patient-Focused Care | Compassion Integrity | Respect | Excellence

Approved by:

JOEL M. ABANILLA, MD Executive Director, PHC

Strategic Impact Position

Core Process

IMPACT

	Impact Indicator	#	Measure	BL	Target	Actual	% ACC
	Healthier Filipino	1	National Cardiac (Heart) Mortality Rate	22.3 % (2013-DOH)	22.0%	No Updated Data	
A	Hearts	2	Health Outcomes RHCs Mortality Z-Benefit Cardiac Surgery	1.1% (1/90)	3.5%	3.2 % (4/124)	109.4 % (3.5/3.2)
		3	Health Outcomes of PHC Net Overall Mortality Rate	4.5 % (699/ 1 <i>5</i> ,588)	5.0%	4.6 % (712/ 15,537)	108.7 % (5/4.6)
В	Better Health Outcomes	4	Decrease mortality from Cardiovascular disease	NA	<5	7.5 % (360/ 8,409)	65.3% (4.9/7.5)
		5	Hospital Acquired Infection Rate	1.10 % (174/15,836)	1.10%	0.63 % (100/ 1 <i>5</i> ,786)	174.6 % (1.10/.63)
c	Responsive Health Systems	6	% of Client with Very Satisfactory Rating	55.4 % (3,657 6,63)	60.0%	57.9 % (4,278/7,390)	96.5 % (57.9/60)
С		7	% NBB-Eligible patients with zero Co payment	90.6 % (<u>1,527</u> 1,686)	93.0%	92.2 % (1,893/2,053)	99.2 % (92.2/93)

STRATEGIC GOAL

	Goal	#	Measure	BL	Target	Actual	% ACC
D	Position Philippine Heart Center as the leader in cardiovascular care at par with global benchmarks	8	Number of cardiovascular procedures with health outcomes at par or better than global benchmarks	3/5	8	16 1. VSD 2. CABG 3. TOF 4. ASD 5. PDA Device 6. PCI Door To Balloon 7. PTC 8. Telecare 9. ASD Device 10.VSD Device 11. Single Valve Repair- Mitral 12. Single Valve Repair- Aortic 13. Endovascular Aneurysm 14. Radio Frequency Ablation Therapy 15. Arterial Switch Operation 16. Neonatal Cardiac Surgery	200.0 % (16/8)
E	Position Philippine Heart Center as the country's lead advocate in the prevention of cardiovascular diseases	9	Number of PHC research/ programs on prevention adopted as national policy	6	7	6 1. VSD 2. CABG 3. TOF 4. Regional Heart Center Program 5. IVIG- KAWASAKI 6. RFRHD	85.7 % (6/7)

CORE PROCESSES # **Objective** Measure BL **Target** Actual % ACC No. of clinical 4 **Provide** pathways CABG 129.4% 17 22 10 comprehensive developed and VSD (22/17)TOF TP implemented and **PDA Device** responsible F patient care Percentage 57.3% 63.5% using multicompliance to (775/1,352)disciplinary 81.9% CABG: 49.3% 70.0% 11 approved clinical CABG: 42.5% VSD: **83.7**% best practice (57.3/70)pathways VSD: 88.4% TOF: 87.3% standards TOF: 93.7% 14 1. Pediatric Cardiology Clinical Research Fellowship 2. Clinical Pathway Workshop for 1. ECC courses Hospitals 2. CV Wellness 3. PGS Module 2 3. ECG courses 4. RERHD Module Number of new 4. Critical Care 8 5. ECC courses 175.0% 12 training programs nursing 6. CV Wellness (14/8)**Expand local** 5. CV Nursing developed 7. ECG courses and 6. CV Lab Training 8. Critical Care nursing Module 9. CV Nursing international 10. CV Lab Training Module 7. PGS Module 1 G training for 11. PGS Module 1 advanced 12. OSM Program/Benchmarking cardiovascular 13. Minimally Invasive Valve Surgery procedures 14. Perfusion Training Program (PTP) • 1 Fellow/ Program • 1 Fellow/ Program Number of • 20 hospitals- PGS • 39 hospitals- PGS graduates of new

Module 1 Module 1 175.0% Fellowship training 13 • 4 hospitals- PGS • 5 hospitals- PGS Module 2 programs / (49/28)Module 2 • 5 hospitals- Clinical Pathway Hospitals with • 4 hospitals-• PTP- 22 completed module Clinical Pathway

CORE PROCESSES

	Objective	#	Measure	BL	Target	Actual	% ACC
	Prioritize institutional research on	14	Number of research outputs published & presented	141.4% (198/140)	90.0%	123.2 % (142/175)	136.9% (123.2/ 90)
н	advanced cardiovascular procedures to impact national health policies	15	Number of research outputs completed for policies on prevention and benchmark procedures	CABG- 1 VSD- 1 TOF- 1 RFRHD- 1 Metabolic Syndrome- 2	4	9	225.0 % (9/4)
	Strengthen linkages with stakeholders for prevention and treatment of CV diseases nationwide	16	Number of independent regional heart centers	2	2	3 1. SPMC 2. VSMMC 3. NMMC	1 50.0 % (3/2)
1		1 <i>7</i>	Beneficiaries of barangay-based PhilPrevent program	1	2	2 1. Sitio Ruby 2 nd Phase Intervention 2. Taguig- RFRHD	100.0 % (2/2)

SUPPORT PROCESSES

	Objective	#	Measure	BL	Target	Actual	% ACC
		18	Percentage increase in employment satisfaction survey	85.0%	90.0%	93.1% (1,634/1,756)	103.4 % (93.1/90)
J	Provide comprehensive Employee Career training and progression pathway to enhance employee engagement	19	Percentage of filled additional plantilla positions	0 #	0	NA	NA
		20	PRIME-HRM Level	LEVEL II	Submit applica- tion for LEVEL III	100.0% (submitted 4/4)	100.0%
	Promote heartfelt	21	Percentage of resolved documented complaints	80.0%	85.0%	94.7 % (54/57)	111.4 % (94.7/85)
K	cardiovascular care through positive patient experience	22	Decrease in patient safety related incidences	2.66% (476 178,889)	2.5%	1.81% (242/133,695)	138.1%
L	Upgrade hospital facilities for L positive practice environment and stakeholders' satisfaction		Percentage of infrastructure projects completed as scheduled	96.7%	95.0%	142.3% (37/26)	149.8% (142.3/95)
М	Provide technology solutions to improve operational efficiency	24	Number of new IT systems utilized by end-users	0 #	10	43	430.0 % (43/10)
		25	Percentage increase in gross revenue	14.9%	12.0%	10.9% (357.6M/ 3.29B	90.8% (10.9/12
N	Ensure prudent and efficient	26	Budget utilization rate	85.0%	100.0%	83.4 % (2.13B/2.56B	83.4%
	asset management	27	CapEx budget utilization rate	55.8%	100.0%	69.7 % (143.0M/205.3M	69.7%
		28	Zero out-of-stock essential drugs and supplies	11.2%	10.0%	3.3 % (3/91)	303.0% (10/3.3)







PERSPECTIVE	2018 Jan-Dec	2019 Jan-Dec
SOCIAL IMPACT (1-7 measures)	166.1%	108.9%
ORGANIZATION (8-9 measures)	160.0%	142.9%
INTERNAL PROCESS (10-11, 20-24 measures)	193.1%	161.9%
PEOPLE EMPOWERMENT (12-19 measures)	168.0	159.3%
FUND RESOURCE (25-28 measures)	76.6%	136.7%
AVERAGE ACCOMPLISHMENT	152.8% Outstanding	141.9% Outstanding



Office of Strategy Management

BALANCED SCORECARD QUARTERLY SUMMARY REPORT

January – December 2019

IMPACT

	Impact		Measure	BL		Actual		% ACC
	Indicator	#	Medsure	DL	Q1-Q2	Q3	Q4	% ACC
A	Healthier Filipino	1	National Cardiac (Heart) Mortality Rate	22.3 % (2013-DOH)	No Updated Data	No Updated Data	No Updated Data	No Updated Data
	Hearts	2	Health Outcomes RHCs Mortality Z-Benefit Cardiac Surgery	1.1% (1/90)	3.5% 1.9% (1/52)	3.5% 4.8% (4/84)	3.5% 3.2% (4/124)	109.4 % (3.5/3.2)
		3	Health Outcomes of PHC Net Overall Mortality Rate	4.5 % (699/ 1 <i>5</i> ,588)	5.0% 5.1% (382/ 7,517)	5.0% 4.8% (555/ 11,509)	5.0% 4.6% (712/ 15,537)	108.7 % (5/4.6)
В	Better Health Outcomes	4	Decrease mortality from Cardiovascular disease	NA	< 5 7.9 % (333/ 4,235)	< 5 7.5 % (491/ 6571)	<5 7.5 % (360/ 8,409)	65.3% (4.9/7.5)
		5	Hospital Acquired Infection Rate	1.10 % (174/15,836)	1.10% 0.72% (55/ 7,634)	1.10% 0.71% (83/ 11,693)	1.10% 0.63% (100/ 15,786)	174.6 % (1.10/.63)
	Responsive Health Systems	6	% of Client with Very Satisfactory Rating	55.4 % (3,657 6,63)	60.0% 56.4% (1,875/ 3,323)	60.0% 56.8% (3081/ 5427)	60.0% 57.9% (4,278/ 7,390)	96.5 % (<i>57</i> .9/60)
С		7	% NBB-Eligible patients with zero Co payment	90.6 % (<u>1,527</u> 1,686)	93.0% 92.0% (888/ 965)	93.0% 92.6% (1442/ 1557)	93.0% 92.2% (1,893/ 2,053)	99.2 % (92.2/93)
		Le	gend: 0 100% and up 0 70%	69%	and below	Targets in red f	onts	

STRATEGIC GOAL

	Goal	#	Measure	BL			Actual	% ACC
					Q1-Q2	Q3	Q4	
D	Position Philippine Heart Center as the leader in cardiovascular care at par with global benchmarks	8	Number of cardiovascular procedures with health outcomes at par or better than global benchmarks	3/5	8 11	8 11	1. VSD 2. CABG 3. TOF 4. ASD 5. PDA Device 6. PCI Door To Balloon 7. PTC 8. Telecare 9. ASD Device 10.VSD Device 11. Single Valve Repair- Mitral 12. Single Valve Repair- Aortic 13. Endovascular Aneurysm 14. Radio Frequency Ablation Therapy 15. Arterial Switch Operation 16. Neonatal Cardiac Surgery	200.0 % (16/8)
E	Position Philippine Heart Center as the country's lead advocate in the prevention of cardiovascular diseases	9	Number of PHC research/ programs on prevention adopted as national policy	6	7 6	7 6	6 1. VSD 2. CABG 3. TOF 4. Regional Heart Center Program 5. IVIG- KAWASAKI 6. RFRHD	85.7 % (6/7)

CORE PROCESSES Objective # % ACC Measure BL Actual Q1-Q2 **Q3 Q4** 4 No. of clinical **Provide** 17 17 129.4% CABG pathways 10 comprehensive VSD developed and 14 22 22 (22/17)TOF and implemented PDA Device responsible F patient care **70**.% **70.**% **70.**% Percentage using multi-63.5% 55.3% 57.3% **52.2%** compliance to 81.9% disciplinary (582/1052)11 approved clinical CABG: 49.3% (775/1,352)(363/95)best practice (57.3/70)CABG: 40.4% VSD: 83.7% CABG: 38.5% CABG: 42.5% pathway standards VSD: 87.3% TOF: 87.3% VSD: 88.4% VSD: 84.7% TOF: 94.5% TOF: 945% TOF: 93.7% 8 14 7 1. Pediatric Cardiology Clinical Research 1. ECC courses **Fellowship** 2. CV Wellness 2. Clinical Pathway Workshop for 3. ECG courses Hospitals 4. Critical Care 3. PGS Module 2 Number of new nursing 4. RFRHD Module 175.0% 10 12 11 training programs 5. CV Nursing 5. ECC courses (14/8)**Expand local** 6. CV Lab 6. CV Wellness developed and 7. ECG courses Training 8. Critical Care nursing international Module 9. CV Nursing G 7. PGS training for 10. CV Lab Training Module Module 1 advanced 11. PGS Module 1 cardiovascular 12. OSM Benchmarking 13. Minimally Invasive Valve Surgery procedures 14. Perfusion Training Program (PTP) Number of 28 graduates of new 49 175.0% 23 **Fellowship** 13 NA • 1 Fellow/ Program trainings/ 27 44 (49/28)• 39 hospitals- PGS Module 1 Hospitals with • 5 hospitals- PGS Module 2 completed module • 5 hospitals- Clinical Pathway

CORE PROCESSES

	Objective	#	Measure	BL		Actual		% ACC
					Q1-Q2	Q3	Q4	
н	Prioritize institutional research on	14	Number of research outputs published & presented	141.4% (198/140)	90.0% 197.0% (130/66)	90.0% 193.8% (126/65) (Jan-Jun)	90.0% 123.2% (142/175)	136.9 % (123.2/ 90
	advanced cardiovascular procedures to impact national health policies	15	Number of research outputs completed for policies on prevention and benchmark procedures	CABG- 1 VSD- 1 TOF- 1 RFRHD- 1 Metabolic Syndrome- 2	4 7	4 7	4 9	225.0 % (9/4)
	Strengthen linkages with stakeholders	16	Number of independent regional heart centers	2	2 3 1. SPMC 2. VSMMC 3. NMMC	2 3 1. SPMC 2. VSMMC 3. NMMC	2 3 1. SPMC 2. VSMMC 3. NMMC	150.0% (3/2)
ı	for prevention and treatment of CV diseases nationwide	1 <i>7</i>	Beneficiaries of barangay-based PhilPrevent program	1	2 1. Sitio Ruby 2 nd Phase Intervention 2. Taguig- RFRHD	2 1. Sitio Ruby 2 nd Phase Intervention 2. Taguig- RFRHD	2 1. Sitio Ruby 2 nd Phase Intervention 2. Taguig- RFRHD	100.0% (2/2)

Objective Measure BL Q1-Q2

Provide comprehensive	18	Percentage increase in employment satisfaction survey	85.0%	90.0% Ongoing Survey	90.0 % 75.0%	90.0% 93.1% (1,634/1,756)	10 (93
Employee Career training		December of Cills I and Items of					

SUPPORT PROCESSES

80.0%

2.66%

96.7%

0

14.9%

85.0%

55.8%

11.2%

13

đ۶

(476

178,889)

NA

100.0%

Ongoing

application

94.7%

(18/19)

1.67%

(144/86,323)

95.0%

85.3%

(29/34)

24

17.3%

(176.1M/1.19B

100.0%

100.0%

2.52%

2.0%

Actual

Q4

NA

100.0%

(submitted 4/4)

94.7%

(54/57)

1.81%

(242/133,695)

142.3%

(37/26)

43

12.0%

10.9%

(357.6M/3.29B)

100.0%

83.4%

(2.13B/2.56B)

100.0%

69.7%

(143.0M/205.3M)

3.3% (3/91)

Q3

NA

100.0%

75.0%

Ongoing Application

85.0%

97.4%

(38/39)

2.5%

1.67%

(144/86,323)

(Jan-Jun)

95.0%

85.3%

(29/34)

(Jan-Jun)

35

12.0%

10.9%

(357.6M/3.29B)

100.0%

30.3%

(Jan-Jun)

100.0%

2.52%

(Jan-Jun)

2.2%(2/91)

% ACC

03.4% 3.1/90)

NA

100.0%

111.4%

(94.7/85)

138.1%

149.8%

(142.3/95)

430.0%

(43/10)

90.8%

(10.9/12)

83.4%

69.7%

303.0%

(10/3.3)

Percentage of filled additional 19 0 plantilla positions 20 PRIME-HRM Level LEVEL II

Percentage of resolved

documented complaints

Decrease in patient safety

related incidences

Percentage of infrastructure projects

completed as scheduled

Number of new IT systems

utilized by end-users

Percentage increase in

gross revenue

Budget utilization rate

CapEx budget utilization

rate

Zero out-of-stock essential

drugs and supplies

and progression pathway

to enhance employee engagement

Promote heartfelt

cardiovascular care

through positive patient

experience

Upgrade hospital

facilities for positive

practice environment and

stakeholders' satisfaction Provide technology

solutions to improve

operational efficiency

Ensure prudent and

efficient asset

management

Κ

M

Ν

21

22

23

24

25

26

27

28



Balanced Scorecard 2018- 2019 Yearend Comparative Report



PERSPECTIVE		2018 Jan-Dec		2019 Jan-Dec		
	Q2	Q3	Q4	Q2	Q3	Q4
SOCIAL IMPACT (1-7 measures)	106.5%	132.3%	166.1%	95.7%	98.6%	108.9%
ORGANIZATION (8-9 measures)	160.0%	160.0%	160.0%	111.6%	126.6%	142.9%
INTERNAL PROCESS (10-11, 20-24 measures)	195.7%	225.1%	193.1%	123.6%	148.8%	161.9%
PEOPLE EMPOWERMENT (12-19 measures)	132.1%	165.7%	168.0%	159.1%	149.2%	159.3%
FUND RESOURCE (25-28 measures)	76.5%	87.4%	76.6%	177.5%	152.7%	136.7%
AVERAGE ACCOMPLISHMENT	134.2% Outstanding	154.1% Outstanding	152.8% Outstanding	133.5% Outstanding	135.2% Outstanding	141.9% Outstanding

	CARDIOVASCULAR PROCEDURES	BENCHMARK	PHC (Jan-Dec)	Office Responsible
2017	Device Closure of Congenital Heart Disease-PDA	0% Morbidity (Cleveland Clinic 2015: 42 cases)	0.76% , (2/262 cases)	DPC- Invasive Cardiology
	PCI Door to Balloon	90 minutes	41.1 minutes (CV Lab data only)	DAC- Invasive Cardiology DAEC- ER
	Percutaneous Transmitral Commissurotomy	< 1% (Phil. Society of CV Catherization Inc)	0 % (0/70)	DAC- Invasive Cardiology
2018	Close Follow-up of Discharged Patients through Telecare Nursing (Focus on post-reportable outcomes after 30 days)	Not Available	97.1 % (2,064/2,126)	Nursing-Telecare
	Minimally Invasive Cardiac Surgery	0% (Cleveland Clinic, 256 Procedures)	4.65% (2/43 cases)	DSA- Surgery
	Device Closure of Congenital Heart Disease-ASD	3%	0 % (0/30)	DPC- Invasive Cardiology
2019	Device Closure of Congenital Heart Disease-VSD	3%	0 % (0/39)	DPC- Invasive Cardiology
	Charle Value Descrip	Mitral-5.8% (Society of Thoracic Surgeons)	3.36 % (8/238)	DSA- Surgery
	Single Valve Repair	Aortic-3.8% (Society of Thoracic Surgeons)	1.35% (1/74)	DSA- Surgery
	Transcatheter Aortic Valve Replacement	5.2% (Society of Thoracic Surgeons, 2015)	7.69 % (1/13)	DSA- Surgery
2020	Endovascular Aneurysm Repair	6.1% (American Heart Association)	2.22 % (1/45)	DSA- Vascular Surgery
	Advanced Heart Failure Therapies			DAEC- Critical Care Division
	Best Practice in Blood Conservation			DAMS- Bloodbank
	Advanced Coronary Revascularization			DAC- Invasive Cardiology
2021	Radio Frequency Ablation Therapy	<2%	1 <i>.75</i> % (9/514) 2009-2018	DAC- EPS
	Cardiovascular Clinical Trial Center			ETRS- Clinical Research
	Arterial Switch Operation	11% (World Database)	10.0%(4/40)	DPC- Clinical & Critical
2022	Neonatal Cardiac Surgery	20% (World Database)	14.5% (8/55)	DPC- Clinical & Critical
	Peripheral Endovascular Revascularization	< 1% (American Heart Association, 2017)		DSA- Vascular Surgery
Legend:	Outcomes at par with global standards Still with lo	w number of cases		

	NATIONAL POLICIES	Office Responsible							
0017	Policy on Health Facility Development of Regional Hospitals for Cardiac Specialty to Ensure Availability of Cardiovascular Care in 17 Regions (DOH)	Corp Plan (OSM)							
2017	Full Treatment of Rare Kawasaki Disease with IVIG for the Prevention of Coronary Aneurysm (Registry, Free IVIG DOH)	DPC							
2018	2018 Philhealth Special Benefit (Free) Secondary Prophylaxis for all RFRHD Patients 5 to 25 years old								
2019	Philhealth Z-Benefit for Primary PCI in STEMI	DAC- Invasive Cardiology							
	Adoption of Employees' Wellness Program for all National Government Agencies	ETRS- Preventive Cardiology							
2020	Philhealth Z-Benefit Coverage for Mitral Valvuloplasty	DPC- Invasive Cardiology							
	Mandatory Neonatal Pulse-Oximetry in Newborns for Early Detection of Critical Congenital Heart Disease as part of Philhealth-covered Newborn Screening	DPC							
2001	Mandatory Screening for all Grade 6 Students for Early Detection of Metabolic Syndrome for Cardiovascular Risk Reduction in Children	DPC							
2021	Philhealth Z-Benefit Coverage for PDA Device Closure	DPC							
2022	Philhealth OPD Package -Mandatory Cardiovascular Risk Screening for CAD for ages 40-45 years old	DAEC- OPD							
Legend : C	Legend : Completed /Achieved On-going Not yet started								

Prepared by

: GLORILYN JOY C. CAROLINO, MA Psy

Planning Officer III

Office of Strategy Management

Reviewed by

: JULIET J. BALDERAS, MD, MSPH

Department Manager

Management Services Department

Noted by

: CRISELE M. GALANG, RN, MAN

Acting Deputy Executive Director

Nursing Services

JOSEPHINE M. GUILLERMO-LOPEZ, CPA, MBA

Deputy Executive Director Hospital Support Services

Approved by

: JØELM. ABANILLA, MD

Executive Director

MARIA BELEN O. CARISMA, MD

Deputy Executive Director

Education, Training and Research Services

GERARDO S. MANZO, MD

Deputy Executive Director

Medical Services